NVL-655 is a novel, brain-penetrant, ALK-selective tyrosine kinase inhibitor (TKI) developed to address emergent treatment resistance and brain metastases while minimizing off-target central nervous ...
NVL-655 is under clinical development by Nuvalent and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase ...
Nuvalent, Inc., a clinical-stage biopharmaceutical company, announced the initiation of the phase 2 portion of ALKOVE-1, its phase 1/2 clinical trial of NVL-655 for patients with ALK-positive ...
The revenue for NVL-655 is expected to reach an annual total of $129 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...
CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
CAMBRIDGE, Mass. - Nuvalent, Inc. (NASDAQ : NUVL), a clinical-stage biopharmaceutical company, announced today the initiation of the Phase 2 portion of its ALKOVE-1 clinical trial, which will test NVL ...
Preclinical characterization of NVL-330, a selective and brain penetrant HER2 tyrosine kinase inhibitor with broad activity on HER2 oncogenic alterations Authors: Yuting Sun 1, Kristin L. Andrews 1, ...
CAMBRIDGE, MA, USA I January 7, 2022 I Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback